Verastem's VS-7375: The New Kid On The KRAS Block
VS-7375, an oral KRAS G12D ON/OFF inhibitor, reached a confirmed ORR of 9 of 22 (41%) at 900 mg in 2L+ mPDAC. How might this ORR translate into survival, and how does VS-7375 compare with daraxonrasib and zoldonrasib?